Evidence map›Paper›PMID 33486569›Full record

ArticleBioprocess and biosystems engineering2021

Pathway engineering of Saccharomyces cerevisiae for efficient lycopene production.

Xian Xu, Jie Liu, Yongling Lu, Haiquan Lan, Liqing Tian, Zhidong Zhang, Chengjia Xie, Ling Jiang

Abstract read
PubMed Publisher
In one paragraph

Article in Bioprocess and biosystems engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Xian XuSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210046, Jiangsu, China.
Jie LiuSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210046, Jiangsu, China.
Yongling LuSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210046, Jiangsu, China.
Haiquan LanSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210046, Jiangsu, China.
Liqing TianState Key Laboratory of Materials-Oriented Chemical Engineering, College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing, 211816, Jiangsu, China.
Zhidong ZhangInstitute of Microbiology, Xinjiang Academy of Agricultural Sciences, Urumqi, 830091, Xinjiang Uyghur Autonomous Region, People's Republic of China.
Chengjia XieSchool of Chemical Engineering, Yangzhou Polytechnic Institute, Yangzhou, 225127, Jiangsu, China.
Ling JiangCollege of Food Science and Light Industry, Nanjing Tech University, Nanjing, 211816, Jiangsu, China. jiangling@njtech.edu.cn.
Nanjing Normal University · CNNanjing Tech University · CNXinjiang Academy of Agricultural Sciences · CNYangzhou Polytechnic Institute · CN

Funding

Basic Scientific R&D Program for Public Welfare Institutes in Xinjiang KY2019023National Natural Science Foundation of China 21978136National Natural Science Foundation of China Youth Fund 31922070Natural Science Foundation of Jiangsu Province BK20171461Natural Science Foundation of Jiangsu Province BK20180038
6 · The paper itself

Abstract

To construct a Saccharomyces cerevisiae strain for efficient lycopene production, we used a pathway engineering strategy based on expression modules comprising fusion proteins and a strong constitutive promoter. The two recombinant plasmids pEBI encoding the fusion genes with an inducible promoter, as well as pIETB with a constitutive promoter and terminator were introduced into S. cerevisiae YPH499 and BY4741 to obtain the four recombinant strains ypEBI, ypIETB, byEBI and byIETB. The lycopene production and the transcription levels of key genes were higher in the BY4741 chassis than in YPH499. Accordingly, the content of total and unsaturated fatty acids was also higher in BY4741, which also exhibited a decrease of glucose, increase of trehalose, increase of metabolite in citrate cycle, and low levels of amino acids. These changes rerouted metabolic fluxes toward lycopene synthesis, indicating that the BY4741 chassis was more suitable for lycopene synthesis. The lycopene content of bpIETB in SG-Leu medium supplemented with 100 mg/L of linolenic acid reached 10.12 mg/g dry cell weight (DCW), which was 85.7% higher than without the addition of unsaturated fatty acids. The constitutive promoter expression strategy employed in this study achieved efficient lycopene synthesis in S. cerevisiae, and the strain bpIETB was obtained a suitable chassis host for lycopene production, which provides a basis for further optimization of lycopene production in artificial synthetic cells and a reference for the multi-enzyme synthesis of other similar complex terpenoids.

Indexed as

Metabolic EngineeringMetabolic Networks and PathwaysSaccharomyces cerevisiaeLycopeneLycopeneChassisConstitutive promoterFatty acidsLycopeneSaccharomyces cerevisiae

Identifiers

PMID33486569
OpenAlexW3124059723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.